AstraZeneca experimental drug meets main goals of breast cancer study
Send a link to a friend
 [October 26, 2022]
(Reuters) - AstraZeneca Plc said on
Wednesday its experimental drug capivasertib was able to help patients
with an advanced form of breast cancer live longer, when combined with
the drugmaker's older cancer treatment Faslodex regardless of biomarker
status.
Results showed the combination met a late-stage study's main goals,
improving progression-free survival in an overall patient group with
advanced HR-positive breast cancer and in a subgroup whose tumours had
alterations in some genes, the company said.
[to top of second column]
|
An AstraZeneca sign is seen at the third
China International Import Expo (CIIE) in Shanghai, China November
6, 2020. REUTERS/Aly Song/File Photo
 (Reporting by Amna Karimi and Pushkala Aripaka in Bengaluru; Editing by
Rashmi Aich)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
